Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Study of Disitamab Vedotin Combination Therapy in Advanced HER2-Positive Gastrointestinal Tumors
ChiCTR2500114011Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal cancer (CRC) and 1 more (3 cohorts), sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoint: Progression Free Survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)biliary neoplasm
Beyond the preview
Go deeper on ChiCTR2500114011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114011.